AimTop Ventures

GruEnergy manufactures silicon-based anode materials for the electrification of autos, power tools, and other consumer goods.

Artly Coffee develops a robot barista that learns various coffee-making techniques from human baristas. The robots are trained by expert human baristas using artificial intelligence to brew specialty coffee. As robots, they eliminate the risks that human contact may pose to public health. Founded in 2020, Artly is based in Seattle, Washington.

Phyla is developing alternative therapies for antibiotics. The focus of most microbiome efforts is to discover beneficial bacteria to add to the microbiome, in order to cure disease or maintain health. However others lack a subtractive function that can remove harmful or disease-causing bacteria, that would allow the microbiome to rebalance and achieve a stable healthy state. Using bacteriophages as a foundation, they are developing a powerful platform that allows us to selectively 'subtract' bad bacteria without harming the good strains present in the community. It's a bit like using a sniper instead of a grenade to take out a bad guy in a crowd of people.

TriagingX is located in Silicon Valley. Their team successfully built the first generation malware sandbox that has been used by many fortune 500 companies for daily malware analysis. They are now building the next generation sandbox and a larger scale advanced analytic system, on a public and a private cloud, that takes malware sandbox behavior outputs, endpoint snapshots, network logs, and outputs from other security products (IDS/IPS, FW, etc.), to provide the most comprehensive analysis for advanced attacks. Their mission is to work closely with their clients to help them always stay ahead of the attacker and to find and fix weaknesses in their networks before any actual attack happens.

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. Learn more at atomwise.com, or connect on Twitter and LinkedIn.

Oculii is creating a next-generation AI software platform for radars that’s exponentially higher resolution, longer range, more accurate, and less expensive than conventional solutions – increasing safety and reliability. The promise of autonomous vehicles depends on high-performance, all-weather, low-cost and scalable perception technology, and Oculii is bringing it to the world. Oculii's AI software amplifies the resolution of any radar platform, enabling high performance perception for the next generation of autonomous systems. Traditional phased array radars have been used for decades and follow a strict size for performance tradeoff - the larger the sensor aperture, the higher the angular resolution. Oculii’s Virtual Aperture Imaging radar technology fundamentally breaks this tradeoff - enabling its sensors to trade increased compute/processing for angular resolution enhancement with the same physical aperture. Leveraging this technique enables Oculii sensors to extract unprecedented accuracy, range, and 4D positioning information from commodity off the shelf low-cost radar elements, bringing high resolution radar imaging to the next frontier. Oculii is backed by some of the top investors and corporations from Silicon Valley, and is working with the leaders in Self Driving Vehicles, Robotics, and Drones - helping them deliver on an autonomous future with an advanced, robust, affordable perception platform.

Magnetic Insight (MI) introduced magnetic particle imaging into the preclinical diagnostic research market enabling quantitative cell tracking, imaging of vascular function, detecting metastatic tumors, visualizing inflammation, CAR-T cell therapies and initial research into regenerative medicine.

NEXT Trucking, a FreightTech pioneer and drayage leader, offers premium shipping experiences to many of the world’s best-known companies. NEXT’s platform connects shippers with freight capacity across drayage, transload, and OTR. Headquartered in El Segundo, CA, NEXT is venture-backed by leaders such as Brookfield Ventures, GLP, and Sequoia Capital. For more information, visit www.nexttrucking.com.